Tazemetostat as Maintenance Therapy After Neoadjuvant Chemotherapy in EZH2-High Triple-Negative Breast Cancer: Exploiting the Post-Chemotherapy Window to Close the Late-Relapse Gap

Zenodo (CERN European Organization for Nuclear Research) 2026 Preprint Open access

Read full text
Authors: Eric Robert Lawson
DOI: 10.5281/zenodo.18884089
Cited by: 0

Abstract

Triple-negative breast cancer (TNBC) presents a reproducible clinical paradox: EZH2-high tumours respond well to neoadjuvant taxane-anthracycline chemotherapy (higher pathological complete response rates) but carry substantially worse long-term outcomes (higher distant relapse at 3-5 years). Both arms of this paradox are confirmed computationally in GSE25066 (n=508; pCR p

Fields of Study & Subjects

Breast Cancer Treatment Studies Epigenetics and DNA Methylation Breast Lesions and Carcinomas

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
6 March 2026
Language
EN
Document type
Preprint